Table 3.
Dosing Ranges in Reviewed Manuscripts.
| Dose (IU) |
||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Author/Year | U/S | 40 | 200 | 300 | 400 | 500 | 800 | 1,000 | 1,500 | 2,000 | 3,000 | 4,000+ | 10,000+ | 100,000+ |
| Yamshchikov/2009 | X | X/B | ||||||||||||
| Charan/2012 | X | X | X | X | X | X | ||||||||
| Jolliffe/2012 | X | X | X | X | X | X | X | X | X | |||||
| Moroti/2012 | X | X | X | X | ||||||||||
| Bergman/2013 | X | X | X | X | X | X | X | X | X | X | ||||
| Larkin/2013 | X/B | |||||||||||||
| Mao/2013 | X | X | X | X | X | X | X | X | X | |||||
| Xiao/2015 | X | X | X | X | X | X | ||||||||
| Zittermann/2015 | X/B | X/B | X/B | X/B | ||||||||||
| Jat/2016 | X | X | X | X/B | ||||||||||
| Martineau/2016 | X/B | X/B | X/B | X/B | ||||||||||
| Vuichard Gysin/2016 | X | X | X/B | X/B | X/B | X/B | ||||||||
| Yakoob/2016 | X/B | X/B | X/B | X/B | ||||||||||
| Autier/2017 | X/B | X/B | X/B | X/B | ||||||||||
| Christensen/2017 | X | X | ||||||||||||
| Martineau/ 2017 | X/B | X/B | X/B | |||||||||||
| Rejnmark/2017 | X/B/IV | |||||||||||||
| Reinehr/2018 | X | X | X | X | ||||||||||
| Jayawardena/2020 | X | X/B/IV | ||||||||||||
| Marzetke/2020 | X/B | X/B | X/B | X/B | ||||||||||
U/S = unspecified; B = bolus dosing; IV = intravenous administration; X indicates the review identifies the use of this dose in the studies they reviewed.